BioSpace News Archive

Business

Bayer Strikes “Mammoth” CRISPR Deal to Bolster Cell and Gene Therapy

Bayer and Mammoth Biosciences forged a strategic collaboration potentially valued at more than $1 billion. The partnership grants Bayer access to Mammoth’s CRISPR technology to develop in vivo gene-editing therapies.

January 10, 2022
·
2 min read
·
Alex Keown
Deals

Takeda Augments IO Portfolio with Third Build-to-Buy Acquisition in a Year

The planned acquisition will give Takeda full access to Adaptate’s antibody-based γδ T cell engager platform, which includes both pre-clinical and discovery assets.

January 10, 2022
·
2 min read
·
Heather McKenzie
Drug Development

Largest Phase III Hemophilia Gene Therapy Trial Yields Positive Results

The results over the two-year evaluation period for its Phase III GENEr8-1 trial showed consistent clinical benefit from using valoctocogene roxaparvovec.

January 10, 2022
·
3 min read
·
Vanessa Doctor, RN
Business

Pfizer Triple-Partners for Future mRNA Vaccines and Genetic Medicines

Around 40% of Pfizer’s portfolio was realized through partnerships, and Monday, the pharma giant announced three more collaborative deals.

January 10, 2022
·
2 min read
·
Kate Goodwin
FDA

U.S. Averaging 700K New COVID-19 Cases Daily as Deltacron Revealed

The U.S. averages more than 700,000 new COVID-19 cases per day. As of Saturday, there were 4.91M cases, more cases in seven days than in April, May, June, and July 2021 combined.

January 10, 2022
·
5 min read
·
Mark Terry
Drug Development

FDA Okays Idorsia Insomnia Drug, Giving Hope to the Sleep-Deprived

The approval was based on data from a broad clinical program of 1,854 adults with insomnia conducted at more than 160 clinical sites in 18 countries.

January 10, 2022
·
2 min read
·
Mark Terry
FDA

Biocon Downplays Mysterious CRL for Insulin Biosimilar

While Biocon intends to address the CRL, the company has not established a timeline for the resubmission of data and hopes that the FDA will rapidly review the BLA when it does submit the data.

January 10, 2022
·
2 min read
·
Alex Keown
Business

Acadia and Stoke Team Up Against Neurodevelopmental Diseases

The collaboration covers several neurodevelopmental targets, including Rett syndrome, SYNGAP1 syndrome, and one other disease yet to be disclosed.

January 10, 2022
·
2 min read
·
Vanessa Doctor, RN
Business

BMS and Century Therapeutics Will Combine Cell Therapy Forces Against Cancer

BMS and Century Therapeutics agreed to collaborate on the research, development, and commercialization of up to four T cell programs for hematologic malignancies and solid tumors.

January 10, 2022
·
2 min read
·
Alvin Clavines
Biotech Beach

Sigyn Therapeutics: Calming and Preventing the Cytokine Storm

Sigyn is not only trying to treat the inflammatory mediators that fuel sepsis; it wants to prevent the life-threatening event from occurring altogether.

January 10, 2022
·
5 min read
·
Heather McKenzie